

# Technical Report No. 66

## Application of Single-Use Systems in Pharmaceutical Manufacturing

2014



# **PDA Application of Single-Use Systems in Pharmaceutical Manufacturing Technical Report Team**

---

## **Authors**

---

**Robert Repetto**, MS, MBA, Team Co-Chair, Pfizer

**Morten Munk**, Team Co-Chair, CMC Biologics

**Stephen Brown**, Ph.D., BE Vaccines

**Jeffrey Carter**, Ph.D., GE Healthcare

**Niels Guldager**, NNE Pharmaplan

**Christian Julien**, MS, Meissner Filtration Products, Inc.

**Duncan Low**, Ph.D., Amgen

**Ingrid Markovic**, Ph.D., Food and Drug Administration

**Jerold Martin**, MS, Pall Life Sciences

**Paul Priebe**, Sartorius Stedim Biotech

**Christopher J. Smalley**, Ph.D., Merck & Co

**Russell Wong**, Ph.D., Bayer HealthCare

## **Contributors**

---

**Robin Alonso**, Genentech

**Eberhard Bill**, Ph.D., Boehringer Ingelheim

**Oki Dzivenu**, GE Healthcare

**Bill Hartzel**, Catalent Pharma Solutions

**Eric Isberg**, ATMI

**Maik Jornitz**, G-Con

**Michael Kraich**, Ph.D., Boehringer Ingelheim

**James Robinson**, Lachman Consultants

**Hillary Russak**, Genentech

**Robert Shaw**, Finvector—FVT Ltd

**Ken Baker**, NewAge Industries Inc.

**Sally Kline**, Ph.D., Amgen

**Mani Krishnan**, EMD Millipore

**Jessica Frantz**, Sartorius Stedim Biotech

**Disclaimer:** The content and views expressed in this technical report are the result of a consensus achieved by the authoring task force and are not necessarily views of the organizations they represent.

# Application of Single-Use Systems in Pharmaceutical Manufacturing

Technical Report No. 66

ISBN: 978-0-939459-69-8

© 2014 Parenteral Drug Association, Inc.

All rights reserved.



# Table of Contents

<b>1.0 INTRODUCTION</b> .....	1	4.8 Materials of Construction .....	23
<b>2.0 GLOSSARY OF TERMS</b> .....	2	4.8.1 Fluid Management .....	28
2.1 Acronyms .....	3	4.8.1.1 Technological Examples .....	28
<b>3.0 POINTS TO CONSIDER FOR SINGLE-USE SYSTEM MANUFACTURING STRATEGY</b> .....	4	4.8.2 Mixing .....	28
3.1 Single-Use Technologies .....	7	4.8.2.1 Technological Examples .....	28
3.2 Business Drivers for the Adoption of Single- Use Systems .....	7	4.8.3 Fermenters and Bioreactors .....	29
3.3 Qualification and Verification of Suppliers, Materials, Components, and Completed Assemblies .....	9	4.8.3.1 Technological Examples .....	29
3.3.1 Product Risk .....	10	4.9 Storage .....	30
3.4 Process Control Strategy Considerations ....	11	4.9.1 Technological Examples .....	31
3.5 Implementation of a Single-Use System ....	11	4.10 Freezing .....	31
3.5.1 Stakeholder Management .....	11	4.10.1 Technological Examples .....	31
3.5.2 Risk Management .....	11	4.11 Filtration .....	32
3.5.3 Process Validation and Verification (PVV)	12	4.11.1 Technological Examples .....	32
3.5.4 Scoping .....	12	4.12 Centrifugation .....	33
3.5.5 Project Execution Plan (PEP) .....	12	4.13 Chromatography .....	33
3.5.6 End-User Requirements .....	12	4.13.1 Technological Examples .....	33
3.5.7 Testing and Documentation .....	12	4.14 Drug Product Final Filling .....	34
3.5.8 Supplier Management .....	12	4.14.1 Technological Examples .....	34
3.5.9 Logistics Control Requirements .....	12	4.15 Isolators .....	35
3.5.9.1 Inventory and Supply Chain Management .	13	4.16 Sampling and Laboratory Analysis .....	36
3.5.9.2 Waste .....	13	4.16.1 Technological Examples .....	36
3.5.9.3 Transportation .....	13	4.17 Transportation .....	37
3.5.9.4 Single Suppliers .....	13	4.17.1 Technological Examples .....	37
3.5.9.5 Change notifications .....	13	4.18 Sensors .....	38
3.5.9.6 Technical Diligence .....	14	4.18.1 Technological Examples .....	38
3.6 Implementation Summary .....	14	4.19 System Integration .....	39
<b>4.0 SINGLE-USE TECHNOLOGIES AND SYSTEM INTEGRATION</b> .....	15	4.20 Supply Chain Integration .....	39
4.1 Introduction .....	15	4.20.1 Factors Which Affect the Quality of Supply Chain .....	39
4.2 Comparison of MUS and SUS .....	15	<b>5.0 QUALIFICATION AND VERIFICATION OF SUPPLIERS, MATERIALS, COMPONENTS, AND COMPLETED ASSEMBLIES</b> .....	40
4.3 SU Components and Assembly .....	16	5.1 Introduction .....	40
4.4 Technical Feasibility and Risk Assessment Framework .....	17	5.2 Risks Associated with Using Single-Use Systems .....	41
4.5 Factors Affecting SUS Design .....	18	5.3 Single-Use System Assembly .....	43
4.5.1 Process Compatibility .....	18	5.4 Supplier Qualification of Single-use Systems .....	43
4.6 Facility Impact for SUS Setup and Deployment .....	20	5.4.1 Supplier Audits and Technical Diligence ..	43
4.6.1 Operational Requirements .....	20	5.4.2 Supplier Quality Agreements and Responsibilities .....	44
4.7 Applications and Technology .....	21	5.5 Qualification of Alternative Suppliers .....	44
4.7.1 Process Connections .....	21	5.5.1 Qualification of Alternative Sources .....	44
4.7.1.1 Technological Examples .....	21	5.5.2 Interchangeability .....	45
		5.5.3 Using Supplier Quality Documentation .....	46
		5.6 Extractables and Leachables (E&L) .....	47
		5.6.1 Material and Supplier Qualification .....	48
		5.6.2 Toxicity of E&L .....	52

5.6.3 Using Supplier Documentation for Extractables .....	52
5.6.4 Extractable Testing Standardization .....	53
5.7 Bovine Spongiform Encephalopathy (BSE)/ Transmissible Spongiform Encephalopathy (TSE) Concerns.....	53
5.8 The Quality Systems of the End User and Supplier .....	53
5.9 Quality Management for Single-Use System Implementation .....	53
5.9.1 Determination of Expiration Date and Shelf Life .....	53
5.9.2 Dealing with Particulates .....	54
5.9.3 Sanitation and Sterilization.....	54
5.9.4 Bioburden Control .....	54
5.10 Sterilization.....	55
5.10.1 Irradiation Sterilization .....	55
5.10.2 Sterilization with Moist Heat.....	55
5.10.3 Sensor Technology .....	56
5.10.4 Qualification and Validation .....	56
5.11 Integrity .....	57
5.11.1 Testing an SUS for Leaks.....	57
5.11.2 Leak Prevention in an SUS .....	58
5.12 Campaigning .....	60

## 6.0 BUSINESS DRIVERS FOR THE ADOPTION OF SINGLE-USE SYSTEMS .....

6.1 Evaluation of Business Drivers .....	61
6.2 Lifecycle Approach.....	61
6.3 Opportunity Cost .....	62
6.4 Cost of Quality .....	62
6.5 Quantitative Evaluation of Business Drivers	62
6.5.1 Process Assessment .....	63
6.5.2 Batch Frequency .....	63
6.6 Operational Model .....	64
6.6.1 Single- or Multiple-Product Facility .....	64
6.7 Total Cost Model .....	64
6.7.1 Shortcut Cost Model Based on Cost of Goods.....	65
6.7.2 Example of a Shortcut Cost Model .....	65
6.7.3 Comprehensive Cost-of-Goods Model .....	66
6.8 Investment Costs .....	66
6.8.1 Process Equipment .....	66
6.8.2 Utility Equipment.....	66
6.8.3 Indirect Equipment Costs.....	67
6.8.4 Facility .....	67
6.8.5 Materials.....	67
6.8.6 Consumables .....	67
6.8.7 Utilities.....	68

6.8.8 Waste .....	68
6.9 QC/QA and Cost of Quality .....	68
6.10 Fixed Operating Costs .....	68
6.10.1 Cost of Capital.....	69
6.10.2 Depreciation.....	69
6.10.3 Staff .....	69
6.11 Project Duration, Time, and Productivity .....	70
6.11.1 Overall Project Duration .....	70
6.11.2 Process Operation Time .....	70
6.11.3 Time Constraints.....	70
6.11.4 Speed of Process Development .....	70
6.11.5 Equipment and Process Validation .....	71
6.11.6 Construction Time.....	71
6.11.7 Self-Assembly.....	71
6.12 Logistics .....	71
6.12.1 Supply.....	72
6.12.2 Storage .....	72
6.12.3 Transportation.....	72
6.12.4 Waste .....	72
6.13 Disposal of an SUS .....	73
6.14 Sustainability.....	74
6.15 The Value Added .....	74
6.15.1 Value-Added Analysis .....	75

## 7.0 IMPLEMENTATION OF A SINGLE-USE SYSTEM....

7.1 Implementation Road Map .....	77
7.2 Implementation Themes.....	80
7.2.1 Stakeholder Management.....	80
7.2.2 Risk Management.....	81
7.2.3 Process Validation and Verification (PVV)	84
7.3 Implementation S3: Scoping .....	85
7.3.1 SUS Strategy .....	85
7.3.2 Business Drivers .....	85
7.3.3 Operating Scenarios and Standardization	86
7.3.4 Process Validation Stage .....	86
7.3.5 Operating Volumes and Storage Requirements.....	86
7.3.6 Hybrid Systems .....	86
7.3.7 Connection Principles .....	86
7.3.8 Campaigning.....	86
7.3.9 Future Deployment.....	86
7.3.10 Sourcing.....	87
7.3.11 Testing Strategy .....	87
7.3.12 Materials.....	87
7.3.13 Shelf-Life Policy .....	87
7.3.14 Procurement .....	87
7.3.15 Storage .....	87
7.3.16 Waste Treatment .....	88
7.3.17 Non-GxP Issues .....	88

7.3.18 Sustainability.....	88	7.6.4 Training .....	101
7.4 Implementation S4: Business Case.....	88	7.6.5 Training Workflow.....	101
7.4.1 Project Execution Plan .....	88	7.6.6 An Example of SUS Training .....	101
7.4.2 Process and Facility Requirements: Basis of Approach .....	89	7.6.7 Safety .....	102
7.4.3 Facility-Level Plan .....	89	7.6.8 Preparation of a Health, Safety, and Environment Plan .....	102
7.4.4 Implementation-Level Plan.....	90	7.6.9 Health and Safety Issues Related to SUS	102
7.4.5 Operational-Level Plan .....	90	7.7 Implementation S7: Launch.....	103
7.4.6 Facility-Level Integration Plan .....	91	7.7.1 Management of Materials.....	103
7.4.7 Equipment-Level Integration Plan.....	93	7.7.2 Routine or Operational Procurement .....	103
7.4.8 Operational-Level Integration Plan .....	94	7.7.3 Technical Diligence .....	104
7.4.9 Technological Survey .....	94	7.7.4 Quality and Technical Agreements.....	106
7.4.10 Supplier Selection and Supply-Chain Review .....	95	7.7.5 Logistics and Storage .....	106
7.4.11 Extractables and Leachables Database...	96	7.7.6 Waste .....	107
7.5 Implementation S5: Development .....	96	7.7.7 Post-launch Review .....	107
7.5.1 User Requirements for Implementation ...	96	<b>8.0 APPENDIX I: OVERALL USER REQUIREMENT SPECIFICATION EXAMPLE .....</b>	<b>108</b>
7.5.2 Preparing User Requirements .....	96	<b>9.0 APPENDIX II: PROJECT EXECUTION PLAN EXAMPLE .....</b>	<b>121</b>
7.5.3 Layout and Design .....	97	<b>10.0 APPENDIX III: TRAINING REQUIREMENTS EXAMPLE.....</b>	<b>135</b>
7.5.4 Specification .....	98	<b>11.0 REFERENCES .....</b>	<b>136</b>
7.5.5 Standardization Policy.....	99		
7.5.6 Extractables and Leachables .....	99		
7.5.7 Procurement .....	99		
7.6 Implementation S6: Testing and Validation	100		
7.6.1 Delivery.....	100		
7.6.2 Installation .....	100		
7.6.3 Qualification .....	100		

## FIGURES AND TABLES INDEX

<b>Figure 3.0-1</b>	Key Decision Areas for an SUS Manufacturing Strategy.....	4	<b>Table 5.2-1</b>	Risk Complexities of SUS Items and Applications.....	42
<b>Figure 3.0-2</b>	Proposed SUS Decision Pathway .....	6	<b>Table 5.5.2-1</b>	Component Interchangeability Evaluation .....	46
<b>Figure 3.0-3</b>	Technical Report Structure Overview....	6	<b>Table 5.5.3-1</b>	Example Supplier Testing and Reference Standards .....	47
<b>Table 4.2-1</b>	Comparison of MU and SU Systems ..	15	<b>Table 5.6.1-2</b>	Example—Quantitation of Extractables from SU Components after 50 kGy Irradiation .....	50
<b>Figure 4.3-1</b>	Anatomy of an SUS .....	16	<b>Table 5.6.1-3</b>	Identified Extractables from Membrane Filter Cartridges from Several Manufacturers .....	51
<b>Figure 4.4-1</b>	Implementation of an SUS and the Assessment of Drug Process and Product Risk .....	17	<b>Table 5.6.1-4</b>	Identification of Extractables from Polyethylene Biocontainers with Ethyl Vinyl Alcohol Interlayer .....	51
<b>Table 4.5.1-1</b>	Assessment of Process Compatibility	19	<b>Figure 5.11.2-1</b>	Investigation of a Bioprocess Container for Leaks .....	58
<b>Table 4.6-1</b>	Assessment of SUS Facility Setup and Deployment .....	20	<b>Figure 5.11.2-2</b>	Identifying the Location of Leaks on a Bioprocessing Container.....	59
<b>Table 4.6.1-1</b>	Assessment of Operational Requirements .....	21	<b>Figure 6.5-1</b>	Cost Comparison Studies Reference Model.....	63
<b>Table 4.7.1.1-1</b>	Functional Categories of Connectors ..	22	<b>Table 6.5-1</b>	Factors That Affect the Process Model ..	63
<b>Table 4.7.1.1-2</b>	Specific Considerations for Connectors .....	23	<b>Table 6.6-1</b>	Factors That Affect the Operational Model .....	64
<b>Table 4.8-1</b>	Plastics Commonly Used in SUS .....	24	<b>Table 6.7-1</b>	Comparative Evaluation of a New Versus Retrofitted Facility During SUS Implementation.....	64
<b>Table 4.8.1.1-1</b>	Specific Considerations for Fluid Management .....	28	<b>Table 6.8.1-1</b>	Contributory Factors to Investment Costs .....	66
<b>Table 4.8.2.1-1</b>	Specific Considerations for Mixing .....	29	<b>Table 6.8.4-1</b>	Main Variable Operating Costs .....	67
<b>Table 4.8.3.1-1</b>	Specific Considerations for Fermenters or Bioreactors .....	30	<b>Table 6.10-1</b>	Main Fixed Operating Costs .....	69
<b>Table 4.9.1-1</b>	Specific Considerations for the Storage of Process Intermediates .....	31	<b>Table 6.13-1</b>	Treating and Discarding Waste from SUSs .....	74
<b>Table 4.10.1-1</b>	Specific Considerations for Freezing...	32	<b>Table 6.15.1-1</b>	Comparison of Value-Added Activities..	75
<b>Table 4.11.1-1</b>	Specific Considerations for Filtration ..	33	<b>Figure 7.1-1</b>	SUS Implementation Road Map.....	78
<b>Table 4.13.1-1</b>	Specific Considerations for Chromatography .....	34	<b>Table 7.1-1</b>	Focus and Output for Each SUS Implementation Stage.....	79
<b>Table 4.14.1-1</b>	Specific Considerations for Drug Product Final Filling.....	35	<b>Figure 7.2.1-1</b>	An Example of a Stakeholder Power Grid.....	81
<b>Table 4.15-1</b>	Specific Considerations for Isolators ..	36	<b>Table 7.2.3-1</b>	Guidelines for the Application of Risk Management During SUS Implementation.....	82
<b>Table 4.16.1-1</b>	Specific Considerations for Sampling and Laboratory Analysis .....	37			
<b>Table 4.17.1-1</b>	Specific Considerations for Transportation.....	38			
<b>Table 4.18.1-1</b>	Specific Considerations for Sensors ...	39			
<b>Figure 4.19-1</b>	System Integration .....	39			
<b>Figure 5.2-1</b>	Example of an Ishikawa Diagram for Determining Risk Sources .....	41			

<b>Table 7.2.3-2</b>	Directional Risk Profile of SUS Items and Applications.....	83	<b>Table 7.4.6-1</b>	Example of a Regulatory Assessment Table.....	92
<b>Table 7.2.3-3</b>	Risk Management and Mitigation in Current and Future SUS Implementation.....	83	<b>Figure 7.5.3-1</b>	Example of SUS Installation Scope Drawing.....	97
<b>Figure 7.2.3-1</b>	SUS Implementation and the Validation Lifecycle .....	84	<b>Table 7.7.3-1</b>	Principle Differences Between a Quality Audit and a Technical Diligence Assessment.....	104
<b>Table 7.4.1-1</b>	Typical Contents of the SUS Project Execution Plan .....	89	<b>Table 7.7.3-2</b>	Some Pertinent Factors for a Technical Diligence Assessment Checklist.....	105
<b>Figure 7.4.5-1</b>	SUS Process and Facility Integration..	90	<b>Table 7.7.3-3</b>	An Interpretation of the SUS Implementation Process .....	106
<b>Figure 7.4.6-1</b>	Process and Facility Considerations for SUS Implementation.....	91	<b>Table 8.4.3.1-1</b>	Sample Room Classifications .....	117



## 1.0 Introduction

Single-use technology, often described as single-use systems (SUSs) or single-use equipment, has the potential to transform pharmaceutical manufacturing by offering tremendous opportunities to reduce cost, improve flexibility or cycle time, and shorten the time needed to build a manufacturing process for new, lifesaving drugs. This success, however, is very much dependent on how effectively the industry approaches the development and implementation of single-use technology. Ultimately, a new drug can only be successful if it is effective, safe, and available. Traditionally, only a comprehensive understanding of the drug product and manufacturing process can achieve these goals. This remains true as SUS is introduced in place of traditional reusable equipment. Encouraging an open science- and risk-based dialogue during supplier audits and evaluation of SUS supply chains significantly improves an SUS implementation.

This document is intended to provide the reader with critical concepts or points to consider when implementing an SUS strategy in a pharmaceutical manufacturing process. These concepts are intended to be valid both for chemically synthesized small molecules and for bioprocesses that produce large-molecule biopharmaceutical products. However, to be truly effective, many of these critical concepts must start with the design, supply chain, manufacturing, and distribution of SUSs themselves, as many inherent quality attributes can impact either the product molecule or its production process. Pharmaceutical manufacturers and single-use technology suppliers have become partners whose success is dependent on the control strategies implemented.

This document discusses SUSs that are in either direct or indirect contact with the raw materials, intermediates, and pharmaceutical drug substances or drug products. The document does not intend to discuss disposable items related to laboratory activities, final delivery system to the patient, transfusion bags, packaging, or medical devices.

Successful SUS implementation needs a comprehensive approach balancing the product and process goals achieved by using single-use technology. Section 3, Manufacturing Strategy, of this technical report is intended to present an approach that ties together key considerations when evaluating single-use technology. A well-designed manufacturing strategy will address technical, quality, business, and implementation considerations. Each topic has a dedicated section in this technical report, providing a detailed discussion of the associated considerations.

Determining the optimal manufacturing strategy involves concepts from many disciplines. An effective evaluation will have a balanced viewpoint, with input from engineering, regulatory, quality, project management, and accounting. Balancing risks and rewards of an SUS over a multiple-use system (MUS) will help determine the most appropriate manufacturing strategy. Thus, a structured science- and risk-based approach is recommended and should be consistent with principles described in ICH Guidelines Q6, Q7, Q8, Q9, Q10, and Q11. Primary goals, when developing any manufacturing strategy, should focus on controlling impacts to patient safety, product availability, and product and process understanding (1–6).

Only a formal partnership with an SUS supplier can ensure that quality is as good as or better than what is achieved with traditional systems (e.g., a purchase order is not a partnership). SUS suppliers provide equipment that includes the outsourced, value-added activities that the end user no longer performs. These value-added activities are important for the success of both organizations, and a winning control strategy for SUS has elements in both the supplier's and the end user's quality systems.

The concepts and recommendations presented in this technical report were developed over several years of discussion within the task force, at PDA workshops, and at other industry meetings. The authors of this technical report recognize that the conversation regarding how best to implement SUSs is just beginning. Ultimately the success of these systems will be determined by the decisions suppliers and end users make during implementation, and the hope is that this report provides a foundation for the industry to build on.